このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Denali Therapeutics マネジメント

マネジメント基準チェック /34

Denali Therapeutics'の CEO はRyan Wattsで、 Aug2015年に任命され、の在任期間は 9.42年です。の年間総報酬は$ 7.88Mで、 8.5%給与と91.5%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の1.56%を直接所有しており、その価値は€ 46.48M 。経営陣と取締役会の平均在任期間はそれぞれ5.6年と7.9年です。

主要情報

Ryan Watts

最高経営責任者

US$7.9m

報酬総額

CEO給与比率	8.5%
CEO在任期間	9.2yrs
CEOの所有権	1.6%
経営陣の平均在職期間	5.8yrs
取締役会の平均在任期間	8yrs

経営陣の近況

Recent updates

CEO報酬分析

Denali Therapeutics の収益と比較して、Ryan Watts の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Jun 30 2024	n/a	n/a	-US$420m
Mar 31 2024	n/a	n/a	-US$137m
Dec 31 2023	US$8m	US$670k	-US$145m
Sep 30 2023	n/a	n/a	-US$124m
Jun 30 2023	n/a	n/a	-US$128m
Mar 31 2023	n/a	n/a	-US$371m
Dec 31 2022	US$9m	US$645k	-US$326m
Sep 30 2022	n/a	n/a	-US$303m
Jun 30 2022	n/a	n/a	-US$284m
Mar 31 2022	n/a	n/a	-US$286m
Dec 31 2021	US$13m	US$610k	-US$291m
Sep 30 2021	n/a	n/a	US$30m
Jun 30 2021	n/a	n/a	US$56m
Mar 31 2021	n/a	n/a	US$58m
Dec 31 2020	US$9m	US$589k	US$71m
Sep 30 2020	n/a	n/a	-US$228m
Jun 30 2020	n/a	n/a	-US$216m
Mar 31 2020	n/a	n/a	-US$215m
Dec 31 2019	US$5m	US$567k	-US$198m
Sep 30 2019	n/a	n/a	-US$66m
Jun 30 2019	n/a	n/a	-US$55m
Mar 31 2019	n/a	n/a	-US$52m
Dec 31 2018	US$6m	US$545k	-US$36m
Sep 30 2018	n/a	n/a	-US$137m
Jun 30 2018	n/a	n/a	-US$123m
Mar 31 2018	n/a	n/a	-US$91m
Dec 31 2017	US$1m	US$481k	-US$88m

報酬と市場: Ryanの総報酬 ($USD 7.88M ) は、 German市場 ($USD 2.47M ) の同規模の企業の平均を上回っています。

報酬と収益: Ryanの報酬は、過去 1 年間の会社の業績と一致しています。

CEO（最高経営責任者

Ryan Watts (48 yo)

9.2yrs

在職期間

US$7,879,267

報酬

Dr. Ryan J. Watts, Ph D., serves as Director at PEEL Therapeutics, Inc. since February 2023. He is the Co-Founder of Denali Therapeutics Inc. and has been its President and Chief Executive Officer since Au...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Ryan Watts	Co-Founder	9.2yrs	US$7.88m	1.57% $ 57.6m
Alexander Schuth	Co-Founder	9.6yrs	US$4.17m	0.41% $ 15.0m
Marc Tessier-Lavigne	Co-Founder & Independent Director	no data	US$431.93k	1.47% $ 54.3m
Carole Ho	Chief Medical Officer & Head of Development	9.3yrs	US$4.17m	0.15% $ 5.4m
Tyler Nielsen	Senior Vice President of Corporate Finance	no data	データなし	データなし
Dana Andersen	Chief Technical and Manufacturing Officer	6.2yrs	データなし	データなし
Joe Lewcock	Chief Scientific Officer	4.3yrs	データなし	データなし
Laura Hansen	Vice President of Investor Relations	4.8yrs	データなし	データなし
Chris Walsh	General Counsel	5.8yrs	データなし	データなし
Mark Rowen	Vice President of Corporate Development	1.8yrs	データなし	データなし
Cindy Dunkle	Chief People Officer	no data	データなし	データなし
Katie Peng	Chief Commercial Officer	3.1yrs	データなし	データなし

5.8yrs

平均在職期間

51yo

平均年齢

経験豊富な経営陣: 4DNの経営陣は経験豊富で経験豊富です（平均在職期間は5.6年）。

取締役

名称	ポジション	在職期間	報酬	所有権
Ryan Watts	Co-Founder	9.6yrs	US$7.88m	1.57% $ 57.6m
Marc Tessier-Lavigne	Co-Founder & Independent Director	9.6yrs	US$431.93k	1.47% $ 54.3m
Vicki Sato	Independent Chairperson	9.5yrs	US$459.43k	0.076% $ 2.8m
Jay Flatley	Independent Director	9.5yrs	US$444.43k	0.24% $ 8.8m
Eric Reiman	Member of Scientific Advisory Board	no data	データなし	データなし
David Schenkein	Independent Director	9.5yrs	US$439.43k	0.051% $ 1.9m
David Holtzman	Member of Scientific Advisory Board	3.9yrs	データなし	データなし
Peter Klein	Independent Director	6.6yrs	US$439.43k	0.011% $ 399.4k
Jennifer Cook	Independent Director	5.9yrs	US$429.43k	0.0098% $ 361.8k
Steve Krognes	Director	2.4yrs	US$419.43k	0.60% $ 22.0m
Scott Biller	Member of Scientific Advisory Board	no data	データなし	データなし
Stacie Weninger	Member of Scientific Advisory Board	3.8yrs	データなし	データなし

8.0yrs

平均在職期間

64yo

平均年齢

経験豊富なボード: 4DNの取締役会は経験豊富であると考えられます ( 7.9年の平均在任期間)。

Denali Therapeutics マネジメント

マネジメント 基準チェック /34

主要情報

経営陣の近況

Denali Therapeutics Inc., Annual General Meeting, May 31, 2024

Insufficient new directors

Co-Founder recently sold €310k worth of stock

Co-Founder recently sold €98k worth of stock

Co-Founder recently sold €136k worth of stock

Insider recently sold €85k worth of stock

Recent updates

Denali Therapeutics Announces Successful Meeting with the FDA and Plans to File for Accelerated Approval of Tividenofusp Alfa (DNL310) for the Treatment of MPS II (Hunter Syndrome)

First half 2024 earnings released: US$1.27 loss per share (vs US$0.53 profit in 1H 2023)

New major risk - Revenue and earnings growth

First quarter 2024 earnings released: US$0.68 loss per share (vs US$0.80 loss in 1Q 2023)

Denali Therapeutics Announces Completion of Enrollment for Regimen G Evaluating Eif2b Agonist Dnl343 in the Phase 2/3 Healey ALS Platform Trial

Denali Therapeutics Inc., Annual General Meeting, May 31, 2024

New minor risk - Shareholder dilution

New major risk - Revenue and earnings growth

Denali Therapeutics Inc. announced that it expects to receive $499.73271 million in funding from Baker Bros. Advisors LP

Denali Therapeutics Inc. announced that it expects to receive $499.73271 million in funding from Baker Bros. Advisors LP

New major risk - Revenue and earnings growth

Denali Therapeutics Announces New Data and Expansion of Its Blood-Brain Barrier-Crossing Enzyme Replacement Therapy Programs At Worldsymposium

Denali Therapeutics Inc. Announces Presentations on Its Investigational Blood-Brain Barrier (Bbb)-Crossing Enzyme Replacement Therapies At the Upcoming 2024 Worldsymposium

Insufficient new directors

Co-Founder recently sold €310k worth of stock

Denali Therapeutics Announces Key Anticipated 2024 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage Diseases

Third quarter 2023 earnings released: US$0.72 loss per share (vs US$0.84 loss in 3Q 2022)

New minor risk - Share price stability

Denali Therapeutics Inc. Announces New Interim Data from Phase 1/2 Study of DNL310 (ETV:IDS) in MPS II (Hunter Syndrome) at SSIEM 2023

New major risk - Revenue and earnings growth

Second quarter 2023 earnings released: EPS: US$1.34 (vs US$0.48 loss in 2Q 2022)

First quarter 2023 earnings released: US$0.80 loss per share (vs US$0.53 loss in 1Q 2022)

Full year 2022 earnings released: US$2.60 loss per share (vs US$2.39 loss in FY 2021)

Denali Therapeutics Announces Presentations on Enzyme Transport Vehicle Development Programs for MPS Diseases at the Upcoming WORLDSymposium™

Co-Founder recently sold €98k worth of stock

Co-Founder recently sold €136k worth of stock

Denali Therapeutics Announces DNL343 Interim Phase 1B Data in ALS and Entry into the Healey ALS Platform Trial

Third quarter 2022 earnings released: US$0.84 loss per share (vs US$0.69 loss in 3Q 2021)

Denali Therapeutics Announces Phase 1/2 Study Single Dose Healthy Volunteer Data with Tak-594/Dnl593 (Ptv:Pgrn) and Progression to Enrolling Participants with Ftd-Grn

Biogen Inc. and Denali Therapeutics Announce Initiation of the Phase 3 Lighthouse Study in Parkinson's Disease Associated with Lrrk2 Pathogenic Mutations

Denali Therapeutics Announces New Interim Data from Phase 1/2 Study of DNL310 (ETV:IDS) in MPS II (Hunter Syndrome)

Insider recently sold €85k worth of stock

Second quarter 2022 earnings released: US$0.48 loss per share (vs US$0.50 loss in 2Q 2021)

Co-Founder recently sold €697k worth of stock

Denali Therapeutics and Biogen Announce Initiation of Phase 2B Study of Lrrk2 Inhibitor in Parkinson's Disease

First quarter 2022 earnings released: US$0.53 loss per share (vs US$0.58 loss in 1Q 2021)

Denali Therapeutics Inc. Announces Achievement of RIPK1 Milestone for Phase 2 Clinical Trial Initiation in ALS by Sanofi

Denali Therapeutics Inc., Annual General Meeting, Jun 02, 2022

Co-Founder recently sold €615k worth of stock

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Co-Founder recently sold €89k worth of stock

Denali Therapeutics Announces Continued Progress in DNL310 (ETV:IDS) Program for MPS II (Hunter Syndrome) Supporting Planned Initiation of Phase 2/3 Clinical Trial

Denali Therapeutics Announces Appointment of Erik Harris to Board of Directors

Denali Therapeutics Inc. Announces U.S. Food and Drug Administration Clinical Hold on DNL919 Investigational New Drug (IND) Application

Co-Founder recently sold €2.5m worth of stock

Third quarter 2021 earnings released: US$0.69 loss per share (vs US$0.54 loss in 3Q 2020)

Co-Founder recently sold €435k worth of stock

Denali Therapeutics Announces Initiation of Phase 1b Study of EIF2B Activator DNL343 in ALS

Denali Therapeutics Announces Publication in Cell on New Approach to Treat FTD-GRN

Insider recently sold €108k worth of stock

Second quarter 2021 earnings released: US$0.50 loss per share (vs US$0.56 loss in 2Q 2020)

Director Jay Flatley sitting on 4 company boards

Director Jay Flatley sitting on 4 company boards

First quarter 2021 earnings released: US$0.58 loss per share (vs US$0.55 loss in 1Q 2020)

Denali Therapeutics Inc. Announces Final Results from Phase 1 and Phase 1B Studies of Its Small Molecule LRRK2 Inhibitor, BIIB122/DNL151

Denali Therapeutics Inc. Announces Fast Track Designation Granted by the U.S. FDA to ETV:IDS (DNL310) for the Treatment of Patients with Hunter Syndrome (MPS II)

New 90-day low: €50.16

Co-Founder recently sold €549k worth of stock

Denali Therapeutics Reports Positive Three-Month Data from Phase 1/2 Study with ETV:IDS (DNL310) in Patients with Hunter Syndrome (MPS II)

Denali Therapeutics Inc. Appoints Nancy Thornberry to the Board of Directors

Denali Therapeutics Inc. Enters into A Settlement Agreement with A Stockholders to Resolve Lawsuit

Denali Therapeutics Announces Appointment of Nancy Thornberry to Board of Directors

Independent Director recently sold €368k worth of stock

New 90-day high: €60.82

Denali Therapeutics Announces First Human Biomarker Proof of Concept for its Transport Vehicle (TV) Technology Achieved in Phase 1/2 Study of ETV:IDS (DNL310) in Hunter Syndrome (MPS II)

Revenue misses expectations

Third quarter 2020 earnings released: US$0.54 loss per share

New 90-day high: €38.86

New 90-day high: €33.49

マネジメント基準チェック /34